These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

721 related items for PubMed ID: 10708863

  • 21. Matrix metalloproteinase-10/TIMP-2 structure and analyses define conserved core interactions and diverse exosite interactions in MMP/TIMP complexes.
    Batra J, Soares AS, Mehner C, Radisky ES.
    PLoS One; 2013; 8(9):e75836. PubMed ID: 24073280
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Drosophila TIMP is a potent inhibitor of MMPs and TACE: similarities in structure and function to TIMP-3.
    Wei S, Xie Z, Filenova E, Brew K.
    Biochemistry; 2003 Oct 28; 42(42):12200-7. PubMed ID: 14567681
    [Abstract] [Full Text] [Related]

  • 26. Roles of membrane type 1 matrix metalloproteinase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of human malignant glioma.
    Nakada M, Kita D, Futami K, Yamashita J, Fujimoto N, Sato H, Okada Y.
    J Neurosurg; 2001 Mar 28; 94(3):464-73. PubMed ID: 11235952
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Structural basis of matrix metalloproteinases and tissue inhibitors of metalloproteinases.
    Maskos K, Bode W.
    Mol Biotechnol; 2003 Nov 28; 25(3):241-66. PubMed ID: 14668538
    [Abstract] [Full Text] [Related]

  • 29. Human mesenchymal stem cells generate a distinct pericellular zone of MMP activities via binding of MMPs and secretion of high levels of TIMPs.
    Lozito TP, Jackson WM, Nesti LJ, Tuan RS.
    Matrix Biol; 2014 Feb 28; 34():132-43. PubMed ID: 24140982
    [Abstract] [Full Text] [Related]

  • 30. Involvement of tissue inhibitors of metalloproteinases (TIMPS) during matrix metalloproteinase activation.
    Nagase H, Suzuki K, Itoh Y, Kan CC, Gehring MR, Huang W, Brew K.
    Adv Exp Med Biol; 1996 Feb 28; 389():23-31. PubMed ID: 8860990
    [No Abstract] [Full Text] [Related]

  • 31. [Expression of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in joint tissues of rapidly destructive coxarthropathy (RDC), analyzed by immunohistochemical study].
    Matsumoto F, Uzuki M, Kaneko C, Rikimaru A, Kokubun S, Sawai T.
    Ryumachi; 1997 Oct 28; 37(5):688-95. PubMed ID: 9396371
    [Abstract] [Full Text] [Related]

  • 32. Biophysical and functional characterization of full-length, recombinant human tissue inhibitor of metalloproteinases-2 (TIMP-2) produced in Escherichia coli. Comparison of wild type and amino-terminal alanine appended variant with implications for the mechanism of TIMP functions.
    Wingfield PT, Sax JK, Stahl SJ, Kaufman J, Palmer I, Chung V, Corcoran ML, Kleiner DE, Stetler-Stevenson WG.
    J Biol Chem; 1999 Jul 23; 274(30):21362-8. PubMed ID: 10409697
    [Abstract] [Full Text] [Related]

  • 33. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed.
    Morgunova E, Tuuttila A, Bergmann U, Isupov M, Lindqvist Y, Schneider G, Tryggvason K.
    Science; 1999 Jun 04; 284(5420):1667-70. PubMed ID: 10356396
    [Abstract] [Full Text] [Related]

  • 34. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions.
    Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP.
    Eur J Cell Biol; 1997 Oct 04; 74(2):111-22. PubMed ID: 9352216
    [Abstract] [Full Text] [Related]

  • 35. Engineering of selective TIMPs.
    Nagase H, Meng Q, Malinovskii V, Huang W, Chung L, Bode W, Maskos K, Brew K.
    Ann N Y Acad Sci; 1999 Jun 30; 878():1-11. PubMed ID: 10415716
    [Abstract] [Full Text] [Related]

  • 36. Matrix metalloproteinases and metastasis.
    Kleiner DE, Stetler-Stevenson WG.
    Cancer Chemother Pharmacol; 1999 Jun 30; 43 Suppl():S42-51. PubMed ID: 10357558
    [Abstract] [Full Text] [Related]

  • 37. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ.
    Ann Biol Clin (Paris); 2003 Jun 30; 61(2):147-58. PubMed ID: 12702469
    [Abstract] [Full Text] [Related]

  • 38. Total conversion of tissue inhibitor of metalloproteinase (TIMP) for specific metalloproteinase targeting: fine-tuning TIMP-4 for optimal inhibition of tumor necrosis factor-{alpha}-converting enzyme.
    Lee MH, Rapti M, Murphy G.
    J Biol Chem; 2005 Apr 22; 280(16):15967-75. PubMed ID: 15713681
    [Abstract] [Full Text] [Related]

  • 39. Engineering minimal tissue inhibitors of metalloproteinase targeting MMPs via gene shuffling and yeast surface display.
    Hosseini A, Kumar S, Hedin K, Raeeszadeh-Sarmazdeh M.
    Protein Sci; 2023 Dec 22; 32(12):e4795. PubMed ID: 37807423
    [Abstract] [Full Text] [Related]

  • 40. Active synovial matrix metalloproteinase-2 is associated with radiographic erosions in patients with early synovitis.
    Goldbach-Mansky R, Lee JM, Hoxworth JM, Smith D, Duray P, Schumacher RH, Yarboro CH, Klippel J, Kleiner D, El-Gabalawy HS.
    Arthritis Res; 2000 Dec 22; 2(2):145-53. PubMed ID: 11062605
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.